NicOx.... in attesa di.....

Sì ... finge di esserlo ... le VERE NEWS che tuti si attendono ( mercato in primis) sono ben altre.

Ormai la tattica di annunci col contagocce che non portano soldi in casa ma solo FUFFA, al mercato interessano poco. :rolleyes:

I dati comunicati oggi, sono una mezza copia di quanto detto in Assemblea Generale del 2010. :-o

che ne sappiamo..........potrebbero essere un primo passo verso un partenariato......:rolleyes::D:D

W&S
 
quindi sia mai che ce ne sia un terzo..

fusse che fusse la volta bbona di ..Ferrer :eek:

ABEMUS CREMINA RETTALE? :lol::lol::lol::lol:


In April 2004, NicOx signed an agreement with Grupo Ferrer for the research, development and marketing of novel nitric oxide-donating anti-inflammatory drugs for the treatment of dermatological diseases.

In May 2006 NCX 1047 was selected as the development candidate in their dermatology collaboration. This selection marked the successful completion of the partners’ research program, announced in September 2005, to identify a novel nitric oxide-donating anti-inflammatory with the potential for an improved risk-benefit ratio in humans.

Under the terms of the agreement NicOx is responsible for the initial synthesis of the new compounds, while Ferrer will be responsible for and fund all further development activities through to registration, under the oversight of a joint development committee. Ferrer has marketing rights for the European Union (including EFTA), Latin America, French-speaking Africa (including Morocco and Algeria) and Egypt and an option on U.S. rights, which it may exercise following the commencement of phase 2 studies. NicOx retains all rights for Asia and has the right to co-market products directly in the European Union and EFTA. NicOx will receive undisclosed development milestones and commercial success fees, plus royalties on the sales of any products resulting from the agreement.
 
ABEMUS CREMINA RETTALE? :lol::lol::lol::lol:


In April 2004, NicOx signed an agreement with Grupo Ferrer for the research, development and marketing of novel nitric oxide-donating anti-inflammatory drugs for the treatment of dermatological diseases.

In May 2006 NCX 1047 was selected as the development candidate in their dermatology collaboration. This selection marked the successful completion of the partners’ research program, announced in September 2005, to identify a novel nitric oxide-donating anti-inflammatory with the potential for an improved risk-benefit ratio in humans.

Under the terms of the agreement NicOx is responsible for the initial synthesis of the new compounds, while Ferrer will be responsible for and fund all further development activities through to registration, under the oversight of a joint development committee. Ferrer has marketing rights for the European Union (including EFTA), Latin America, French-speaking Africa (including Morocco and Algeria) and Egypt and an option on U.S. rights, which it may exercise following the commencement of phase 2 studies. NicOx retains all rights for Asia and has the right to co-market products directly in the European Union and EFTA. NicOx will receive undisclosed development milestones and commercial success fees, plus royalties on the sales of any products resulting from the agreement.

SON 2 ANNI CHE LO DICONO ... SENZA AVANZAMENTI DI FASE :-o
 
il prox sarà l'anno buono........:D:help::-o

Sì sì ... partiamo in fase 1 ...

Ah in merito alla procedura EMEA un chiarimento :

A maggio EMEA ha chiesto chiarimenti e NicOx ha tempo fino a fine novembre per rispondere. EMEA dà la risposta entro 2 mesi dalla ricezione dei chiarimenti da parte di Nicox ( quindi fine gennaio 2011) , e potrà chiedere ulteriori approfondimenti, e dove Nicox potrà rispondere in un tempo di 1-3 mesi massimo.

Quindi tra marzo e maggio 2011 dovremmo avere la risposta di EMEA.
 
La fine di Cell ?

Se la notizia è vera, ho paura che facciamo la stessa fine di cell:

http://www.boursorama.com/forum-nicox-professeur-white-a-signe-un-brevet-404092424-1

Buona giornata a touch


Professeur WHITE a signé un Brevet
Auj. à 10:54
au nom de Nicox. (Je suis au boulot, je peux pas retrouver le site...)

Cosignataire avec Mme DUQUESROIX de Nicox

Brevet édité en Octobre 2010, mais qui avait été enregistré en Mars (avant l'avis des experts).

Il est impliqué, le garçon !
 
..e sappiamo già che ad oggi questi chiarimenti non son stati forniti ?!?


Se sono stati forniti, comunque le Big Pharma non si stanno fidando del dossier.

Ciò non significa che non potrebbe essere approvato in farmacovigilanza, ma senz'altro è un indicatore molto importante da tenere in considerazione.
 

Users who are viewing this thread

Back
Alto